Contact Us

Privacy Policy

Use of this website is subject to the following terms and conditions which you are deemed to accept by continuing to browse these pages. If you do not agree to these terms and conditions, please leave this site now.

The Miscarriage Clinic does not sell, rent or loan any identifiable information regarding customers to any third party without your consent.

Any information that you give us is held with the utmost care and security. It will not be used in ways to which you have not consented.

Use of Information

As a user of our site you will always have control of the data we collect about you. However, there will be areas of the site that will require you to provide certain information for you to be able to use or access them. We will not collect any information about individuals, except where it is specifically and knowingly provided by them. Examples of such information are:

Name Address
Telephone number
Email address

Site & Content Personalisation

We will use information that you provide about yourself and your preferences to try and provide you with web content which we believe to be relevant and of interest to you.

Analysis

Data collected via the Internet may be used to carry out analysis that will allow us to monitor the success of our service and plan future site content and activity. Data will also be used to allow us to profile our customers to understand their requirements better and to help us improve our service.

‘Cookies’

The Miscarriage Clinic use a feature of your Internet Web Browser called a ‘Cookie’ on our site. A Cookie is a file that your Web Browser places on your computer’s hard disc which allows us to help you get the best out of your visit to the site. The Miscarriage Clinic uses ‘Cookies’ to make accessing the site more convenient. The Miscarriage Clinic Cookie will remain on your hard disk indefinitely. Most browsers accept cookies automatically. Cookies can be deleted from your browser, or if you would prefer, by amending your browser settings you can prevent their automatic receipt. Please note that we do not use Cookies to retrieve personal information about you from your computer, unless the information has been knowingly and willingly been provided by you.

How to opt-out of receiving communications

If you would prefer to make your opt-out request in writing please send all correspondence to the following address;

Centre for Reproductive Immunology and Pregnancy (CRP Clinic)
Bramshott House
137-139 High Street
Epsom
Surrey
KT19 8EH

Your rights

In addition to The Miscarriage Clinic safeguards, your personal data is protected in the UK by the Data Protection Act. This provides, amongst other things that the data we hold about you should be processed lawfully and fairly. It should be accurate, relevant and not excessive. The information should, where necessary, be kept up to date and not retained for longer than is needed. It should be kept securely to prevent unauthorised access by other people. You have the right to see what is held about you and correct any inaccuracies.

Policy Changes

Any changes to this policy will be posted here.

Links to External Websites

The Miscarriage Clinic accepts no responsibility for the content of any site to which a hypertext link from this site exists. Such links are provided for your convenience on an “as is” basis with no warranty, express or implied, for the information provided within them.

Security

The Miscarriage Clinic treats all the data held with the utmost care and security. Any details you give will remain completely confidential.

More Details

Please read it carefully to understand how your personal information will be treated. We will be the “controller” of the personal information which you provide to us or which we collect from you.

1. Personal information that we collect

We collect a range of personal information relating to you, including your:

  • name;
  • email address;
  • telephone number;
  • credit or debit card information and/or other payment information;
  • delivery and billing address;
  • IP address; and
  • any other personal information that you choose to provide to us when you complete our online contact forms or otherwise make contact with us.

2. How we use your personal information

We use your personal information as follows:

  • to maintain our relationship with you whilst you are a customer;
  • to process orders and provide agreed goods and services to you;
  • for invoicing, processing payments, account set up and maintenance, to communicate with you, including to respond to information requests/enquiries submitted and/or to obtain your feedback on our products and services;
  • for record keeping, statistical analysis and internal reporting and research purposes;
  • to ensure data security and to provide you with access to secure areas of our Websites;
  • to notify you about changes to our products and services; to decide on and notify you about price changes;
  • to monitor the quality of our products and services;
  • for logistical purposes, including to plan and log delivery routes;
  • to investigate any complaint you make; to provide evidence in any dispute or anticipated dispute between you and us;
  • to customise various aspects of our Websites to improve your experience;
  • to pre-complete online forms on our Websites. For example, if you have provided an address when using one service, the Websites computers may automatically fill in that information on an order form for another service;
  • as we may otherwise consider necessary to support the operation of our Websites;
  • to obtain credit references, credit checks and for debt collection, fraud detection and prevention and risk management purposes;
  • to monitor and/or record telephone conversations to or from you in order to offer you additional security, resolve complaints, improve our service standards and for staff training purposes;

3. Security

We use reasonable security methods to protect the personal information that we process, including Internet standard encryption technology (“SSL“ or “Secure Socket Layer“ technology) to encode personal information that you send to us through our Websites. SSL works by using a private key to encrypt data that‘s transferred over the SSL connection. To check that you are in a secure area of the Website before sending personal information to us, please look at the bottom right of your website browser and check that it displays an image of a closed padlock or an unbroken key.

However, please note that whilst we take appropriate technical and organisational measures to safeguard the personal information that you provide to us, no transmission over the Internet can be guaranteed to be secure. Consequently, please note that we cannot guarantee the security of any personal information that you transfer to us over the Internet.

4. Your rights

The following section explains your rights. The various rights are not absolute and each is subject to certain exceptions or qualifications.

We will grant your request only to the extent that it follows from our assessment of your request that we are allowed and required to do so under data protection laws. Nothing in this Privacy Statement is intended to provide you with rights beyond or in addition to your rights as a data subject under data protection laws.

  •  1. The right to be informed – You have the right to be provided with clear, transparent and easily understandable information about how we use your personal information and your rights. This is why we’re providing you with the information in this Privacy Statement.
  •  2. The right of access – You have the right to obtain a copy of your personal information (if we’re processing it), and other certain information (similar to that provided in this Privacy Statement) about how it is used. This is so you’re aware and can check that we’re using your personal information in accordance with data protection law. We can refuse to provide information where to do so may reveal personal information about another person or would otherwise negatively impact another person‘s rights.
  •  3. The right to rectification – You can ask us to take reasonable measures to correct your personal information if it’s inaccurate or incomplete. E.g. if we have the wrong date of birth or name for you.
  •  4. The right to erasure – This is also known as ‘the right to be forgotten’ and, in simple terms, enables you to request the deletion or removal of your personal information where there’s no compelling reason for us to keep using it or its use is unlawful. This is not a general right to erasure; there are exceptions, e.g. where we need to use the information in defence of a legal claim.
  •  5. The right to restrict processing – You have rights to ‘block’ or suppress further use of your personal information when we are assessing a request for rectification or as an alternative to erasure. When processing is restricted, we can still store your personal information, but may not use it further. We keep lists of people who have asked for further use of their personal information to be ‘blocked’ to make sure the restriction is respected in future.
  •  6. The right to data portability – You have rights to obtain and reuse certain personal information for your own purposes across different organisations. This enables you to move, copy or transfer your personal information easily between our IT systems and theirs (or directly to yourself) safely and securely, without affecting its usability. This only applies to your personal information that you have provided to us that we are processing with your consent or to perform a contract which you are a party to (such as pay and compensation services), which is being processed by automated means.
  •  7. The right to object – You have the right to object to certain types of processing, on grounds relating to your particular situation, at any time insofar as that processing takes place for the purposes of legitimate interests pursued by CRP Clinic or by a third party. We will be allowed to continue to process the personal information if we can demonstrate “compelling legitimate grounds for the processing which override [your] interests, rights and freedoms” or we need this for the establishment, exercise or defence of legal claims.
  •  8. Rights in relation to automated decision making and profiling – You have the right not to be subject to a decision based solely on automated processing (including profiling), which significantly affects you, subject to some exceptions. Where this is the case, you have the right to obtain human intervention, voice your concerns and to have the decision reviewed.

Clinic Fees

  • Initial consultation – £370 (a deductible £100 deposit is required to secure this appointment)
  • Follow up consultation – £210
  • Immune tests – tests range from £160 to £735 each
  • Wellbeing tests – tests range from £65 to £215 each
  • Hormonal tests – tests range from £90 to £260 each
  • Non-invasive Fetal DNA testing – £470
  • Initial scan – £245
  • 3D saline scan – £475
  • HyFosy – £500
  • 3D saline scan + Hyfosy – £655
  • Early pregnancy scans (includes consultation) – £305
  • 3D ultrasound scan (with AFC) – £350
  • Nuchal scan (includes blood tests) – £360
  • Anomaly scan – £360
  • Growth scans package (28, 32 and 36 weeks) – £760

    Fetal Medicine scan packages are available on request.

  • Manual Vacuum Aspiration (MVA) – from £2,000
  • Hysteroscopy – from £1,365
  • Initial consultation –  £300
  • IVF Returning patient Consultation – £275
  • Pre-IVF scan and consent check for HFEA forms – £350
  • IVF Follow up Consultation – £225
  • IVF cycle –  From £3,950 (excludes initial and nurse consultations medications,  pre-IVF investigation tests)

    IVF packages are available on request
  • Initial consultation – £285
  • Nurse consultation – £200
  • IUI cycle –  From £1,200 (excludes initial and nurse consultations medications,  pre-IUI investigation tests)

    IUI packages are available on request

  • Sperm DNA Integrity – £515
  • Semen Analysis – £235

Procedures

  • Hysteroscopy (no sedation) – £1765

  • Hysteroscopy (sedation) – £1830

  • Operative Hysteroscopy + removal of polyp or adhesion – £3300

  • Operative Hysteroscopy (sedation) – £3435

Clinician Fees

  • Mr Jan Consultation + Ultrasound if required pre-Hysteroscopy – £475

Anaesthetist Fees

  • Dr Shetty – £300

  • Dr Girgis – £250

  • Dr Muddanna – £250

Additional Fees

  • Products of conception (PROC) – £465
  • Cat1 Histology – £237
  • Hyalobarrier Gel + Antibiotics – £300
  • Handling Fees – £35
  • Penthrox – £75

Insurance Information

Utrogestan

Utrogestan contains progesterone, which is a natural female sex hormone, produced in the body. It works by adjusting the hormone balance within the body. It is used in different indications related to pregnancy such as IVF and pre-term birth. Recent findings have suggested that women who are at risk of a miscarriage because of current pregnancy bleeding and a history of a previous miscarriage, could also benefit from progesterone treatment.

Given as routine to all women with history of recurrent pregnancy loss or preterm labour.

400mg, oral tablets, started around the time of ovulation until 16 weeks of pregnancy.
In some cases, Utrogestan may be used until 34 weeks.

Should be used with caution with diabetes, epilepsy, hypertension, migraine and cardiac dysfunction.

Bloating, fluid retention, breast tenderness, cramp-like pains due to gastric disturbances and skin irritation, possible menstrual cycle irregularities.

Hydroxychloroquine

Hydroxychloroquine was originally an anti-malaria drug used in the 1940s but more recently has found a place in the treatment of conditions such as Rheumatoid arthritis and Lupus. This is because it has immune properties and seems to calm down inflammation. We have used it against Natural Killer Cells with possible help in women with miscarriages and fertility conditions. There are several publications which have shown its benefit in reducing risk of miscarriages and other immune related complications in pregnancy.

This drug could be considered in complex cases or if there are contraindications to use prednisolone.

300–400mg oral tablets. Usually started 4-6 weeks prior to pregnancy. A higher (loading dose) may be required for the first two days of use. The duration of the therapy will be based on individual circumstances.

Neurological disorders (especially in epilepsy), severe gastro-intestinal disorders and G6PD deficiency. Not to be used with azithromycin antibiotics.

Gastro-intestinal disturbances, headache and skin reactions, visual changes, hair loss and pigmentation of the skin, nails and mucous membranes.

You will be required to organise a pre-treatment eye examination and every 6 months whilst taking hydroxychloroquine at your local optometrist. Three monthly wellbeing bloods will be performed.

Most of our patients have tolerated this medication well and it has a good track record in pregnancy with no apparent fetal harm. If you are taking omeprazole, please ensure that you take the two medications at different times as it may inhibit absorption of the hydroxychloroquine.

Intralipid Infusion

Intralipid infusion therapy is a sterile fat emulsion containing soya oil, chicken egg yolk, glycerine and water. The infusion is in liquid form and administered through the veins with an intravenous(IV) cannula*.

The procedure is carried out in the Epsom clinic only as part of your treatment programme. Although not subjected to controlled trials, there are observed benefits in women with miscarriages and fertility conditions.

*Peripheral intravenous (IV) cannulation is an invasive procedure, and risks include phlebitis which may lead to pain or swelling at the infusion site.

Used as part of the treatment programme for high or complex NK cells.

If intralipids are to be included as part of your plan, these will need to be administered
within the CRP Clinic at Epsom where we follow strict clinical guidelines during preparation, administration and delivery of your intralipid therapy to maintain the highest levels of patient safety. Poor safety standards can lead to the introduction of micro-organisms, which may cause infection and other associated risks, including sepsis.

100ml bag of 20% intralipid given as an intravenous dose over 1 hour. The infusion may be required before ovulation, at positive pregnancy test and then repeated every 4 weeks until
20 weeks of pregnancy.

Allergies to Eggs or Soya. Liver disease.

Note: It is important to inform staff if you have had an illness such as a viral infection or diarrhoea and vomiting in the 48 hours prior to your infusion.

Headaches, dizziness, flushing, drowsiness, nausea, vomiting or sweating.
It is rare to have side effects in well patients.

Common side effects we have observed in our patients have included pain/swelling/redness at the infusion site and temperature fluctuations.

Serious side effects (more likely to occur in patients that require this medication on a regular basis for other health issues unlike fertility or miscarriage patients) include: signs of infection (fever, persistent sore throat), injection site reactions (pain, swelling, redness), pain/swelling/ redness of arms and legs, bluish skin, sudden weight gain, shortness of breath, back or chest pain, mental/mood changes, bone pain, muscles weakness, yellowing of skin and eyes, dark urine, bruising or bleeding, severe stomach or abdominal pain.

Omeprazole

This drug belongs to a group called ‘proton pump inhibitors’. They work by reducing the amount of acid that your stomach produces. Omeprazole is mainly used to help reduce the acidic effect of steroids in the stomach.

For patients started on steroids such as Prednisolone, omeprazole is advised to prevent ulcers from forming in the stomach or gut lining.

20mg tablet once a day before breakfast.

Omeprazole is widely used in pregnancy. It is not known to be harmful to an unborn baby.

Headache, effects on your stomach or gut such as diarrhoea, stomach pain or constipation. Nausea and or vomiting.

Fragmin

Fragmin belongs to a group of medicines called low molecular weight heparins, which helps prevent the formation of blood clots by thinning the blood. It is widely used in pregnancy for reducing the risk of blood clots in the mother and in conditions associated with baby growth restriction.

Routinely prescribed in women undergoing treatment with IVF/ICSI and in cases of thrombophilia.

Dose is determined by weight, usually ranging between 5000 and 10 000 units, taken by subcutaneous injections once daily, taken between 6-9pm. Duration of medication is decided on a case-by-case basis.

Manufacturer advises caution in severe hepatic and renal impairment. Not known to be harmful in pregnancy; caution in patients with hypersensitivity to low molecular weight heparins.

Haemorrhage, skin necrosis, low platelets, high potassium, hypersensitivity reactions (including urticaria, angioedema and anaphylaxis); osteoporosis after prolonged use
(and rarely alopecia).

Blood clotting levels ad your full blood count will be checked at 3 monthly intervals.

Prednisolone

Prednisolone belongs to a group of medicines called steroids (corticosteroids). These steroids occur naturally in the body to maintain health and well-being. Boosting your body with extra steroids is an effective way in reducing inflammation. Steroids have widely been used in the treatment of recurrent miscarriage and fertility conditions with varying degrees of success in outcome.

Prednisolone is prescribed to women with recurrent miscarriage or repeated failed assisted conception attempts in the presence of abnormal immune markers such as high NK cells.

The dose usually ranges between 15 and 25mg, and is taken after breakfast. When you have been taking this dose for 3 or more weeks, you will need to wean off the medication by dropping 5mg every 5 days.

Caution is necessary when prescribing prednisolone to patients with the following conditions: adrenal suppression and infection; hypertension, congestive heart failure, liver failure, renal impairment, diabetes mellitus, osteoporosis (post-menopausal women at special risk), glaucoma, psychiatric reactions, severe affective disorders, epilepsy, peptic ulcer, hypothyroidism, history of steroid myopathy.

Prednisolone is compatible with each trimester of pregnancy. Steroids vary in their ability to cross the placenta; 88% of prednisolone is broken down by the placenta and inactivated, therefore very little passes to the baby. There is no evidence that corticosteroids result in an increased incidence of congenital abnormalities, such as cleft palate/lip.

The most common complication is difficulty sleeping at night. Gastrointestinal discomfort, headaches, nausea, altered mood, skin reactions, fatigue, increased weight.

Other Uncommon Side Effects Include

Gastro-intestinal effects include dyspepsia, peptic ulceration, abdominal distension, acute pancreatitis, oesophageal ulceration and candidiasis.

Musculoskeletal effects include proximal myopathy, osteoporosis, vertebral and long bone fractures, avascular osteonecrosis, tendon rupture.

Endocrine effects include adrenal suppression, menstrual irregularities and amenorrhoea, Cushing’s syndrome, hirsutism, weight gain, negative nitrogen and calcium balance, increased appetite, increased susceptibility to and severity of infection.

Neuropsychiatric effects include euphoria, psychological dependence, depression, insomnia, increased intracranial pressure, psychosis and aggravation of schizophrenia, aggravation of epilepsy.

Eye effects include glaucoma, papilledema, posterior subcapsular cataracts, corneal or scleral thinning and exacerbation of ophthalmic viral or fungal disease.

Other side-effects include impaired healing, skin atrophy, bruising, striae, telangiectasia, acne, myocardial rupture following recent myocardial infarction, fluid and electrolyte disturbance, leucocytosis, hypersensitivity reactions, thromboembolism, nausea, malaise, shingles, hiccups.

Further Information: Please be aware that steroids can mask the common symptoms of pregnancy, such as pregnancy sickness.

Wellbeing blood tests are required at 3 monthly intervals.

Aspirin

Aspirin is one of a group of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). It’s widely used to relieve mild to moderate pain and inflammation. It is also widely used in pregnancy for different indications such as reducing the risk of miscarriage, pre-eclampsia, and baby’s growth restriction in women at high risk of these disorders.

In our experience, Aspirin has been shown to reduce the risk of miscarriage, irrespective of outcome of the thrombophilia investigations. It is also used by fertility centres for women undergoing fertility treatment (IVF).

The low dose aspirin we recommend is 75 mg to be taken daily between 6-9 pm after food. Usually, the medication is taken until 20 weeks of pregnancy, but depending on the individual risk of preeclampsia (high blood pressure in pregnancy), the dose may be increased to 150 mg from 12 weeks gestation and continued until 36 weeks.

Not advisable to take if you suffer from asthma, stomach ulcers, known bleeding disorders,
or have mild to moderate renal/hepatic impairment.

Use of low-dose aspirin at any stage of pregnancy has not been associated with harmful effects.

Generally mild and infrequent, but in hypersensitive patients, side effects can include indigestion, heartburn, bloating, gastrointestinal upset with slight asymptomatic blood loss. In severe cases, it can cause an asthma attack and in rare cases, some skin reactions.

GCSF

Granulocyte-Colony Stimulating Factor (G-CSF) is a cytokine (molecules that aid cell-to-cell communication in immune responses and stimulate the movement of cells towards sites of inflammation) that stimulates neutrophilic granulocyte proliferation.

Found to possibly reduce the risk of miscarriage. Based on research trials, G-CSF has been shown to be safe and well-tolerated for mothers throughout pregnancies and for newborns without signs of abnormality. No noticeable side effects were reported.

In certain studies, G-CSF was used in a series of women with unexplained recurrent miscarriage in whom previous treatment with other therapies had failed. It showed G-CSF to be effective in recurrent miscarriage. In one particular study, 29 out of 35 women delivered a healthy baby, whereas in the placebo group, this figure was 16 out of 33. However, further studies are needed to confirm the effectiveness of this treatment in women with unexplained recurrent miscarriage.

The 300 mcg injection is for subcutaneous use. Your doctor will provide instructions on the timing of the injections in line with your treatment plan.

  • Bone pain in areas such as your pelvis, back, arms, or legs.

  • Headache, red or itchy skin (especially around the area where the injection was given).

  • Fever and chills. Over-the-counter painkillers, like paracetamol, can help reduce your temperature and prevent chills.

  • Swelling of the ankles or legs due to fluid retention, which, if severe, could cause breathlessness.

You will need to have a blood test to check your full blood count every 2 weeks whilst on this medication.

Adalimuab

Adalimumab is a TNF blocker, which is used for patients with elevated levels of TNF cytokines or Natural Killer (NK) cells, such as connective tissue disorders. It has been recommended and clinically beneficial in some patients with immune disorders associated with high TNF (tumor necrosis factor) levels.

The women at risk show alterations in CD56+ natural killer cells that secrete tumor necrosis factor. There have been no large studies done on patients with recurrent pregnancy loss or infertility, but several peer-reviewed publications have shown benefit in such conditions.

In cases of high TNF alpha: IL-10 and/or high INF-gamma: IL-10.

Two 40 mg subcutaneous injections: one at a time, 2 weeks apart. Occasionally, this course may be repeated if the TNF alpha: IL-10 or INF-gamma: IL-10 level is still high following the initial two injections.

Predisposition to infection.

Rash, nausea, vomiting, gastric disturbances, infections, headaches, rashes, and shingles.

Adalimumab has been shown not to cause fetal harm and is considered safe in pregnancy if used prior to 32 weeks’ gestation.

  1. If you are satisfied with the information given and have made an informed decision, you will be asked to complete a consent form prior to the arrangement of the prescription.

  2. Once the Adalimumab is received, the first injection can be self-administered, and the other injections stored in the fridge. Adalimumab can be given at any time in your cycle as a subcutaneous injection in the stomach or thigh area.

  3. The second injection is to be administered 2 weeks later.

  4. A further blood test for TNF alpha (HS5) may be needed and arranged after a minimum of 2 weeks following the second injection.

  5. A follow-up appointment is to be made with Professor Shehata 1–2 weeks after the blood test.

All patients, prior to the Adalimumab injections, will have a TB Gold Quantiferon test to ensure that this is negative.

If this is inconclusive, we will need to repeat the test. If TB is positive, then the patient may be referred to a chest physician for assessment and possible tuberculosis treatment prior to receiving the medication.

The TB test takes 5–7 working days to return, after which we will inform you of the result.

Thank You!

Thank you for reaching out to us and completing the enquiry form on our website. We appreciate your interest in our services and understand the importance of this journey for you.

Our team is dedicated to providing you with the support and care you need. One of our specialists will review your enquiry and get back to you to discuss your needs and answer any questions you may have.

We look forward to assisting you and being a part of your journey towards building your family.

Professor Hassan Shehata

Professor Hassan Shehata is a Consultant Obstetrician and Gynaecologist, specialised in Maternal Medicine at Epsom and St. Helier University Hospitals NHS Trust. With an extensive CV, he has contributed his expertise to various hospitals within the UK, building a wealth of experience in obstetrics and gynaecology.

In addition to his diverse clinical background, Professor Shehata is the CEO and Medical Director of the CRP Clinic. He has a wealth of global health contributions including reducing medicalisation of Female Genital Mutilation. He has dedicated his professional life to investigating and treating recurrent miscarriages and addressing challenges associated with failed IVF attempts.